` CDNA (CareDx Inc) vs S&P 500 Comparison - Alpha Spread

CDNA
vs
S&P 500

Over the past 12 months, CDNA has underperformed S&P 500, delivering a return of -29% compared to the S&P 500's +16% growth.

Stocks Performance
CDNA vs S&P 500

Loading
CDNA
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
CDNA vs S&P 500

Loading
CDNA
S&P 500
Difference
www.alphaspread.com

Performance By Year
CDNA vs S&P 500

Loading
CDNA
S&P 500
Add Stock

Competitors Performance
CareDx Inc vs Peers

S&P 500
CDNA
ABBV
CYTH
AMGN
GILD
Add Stock

CareDx Inc
Glance View

Market Cap
722.1m USD
Industry
Biotechnology

CareDx Inc. is a vibrant player in the biotech landscape, navigating the intricate world of transplant medicine with a unique focus on precision diagnostics. Founded in 1998 and headquartered in South San Francisco, CareDx is deeply entrenched in the development of solutions that enhance the longevity and quality of life for organ transplant recipients. Their flagship offerings, such as AlloMap and AlloSure, are non-invasive, blood-based tests that provide critical insights into the functioning and health of transplanted organs. These tests are pivotal in assessing transplant recipients for possible organ rejection, thus presenting rapid, reliable data that may preempt irreversible damage. CareDx captures value by providing these sophisticated diagnostic tests and services to transplant centers that require cutting-edge technology to improve patient outcomes. Revenue generation for CareDx is anchored in its comprehensive commercial approach, developing partnerships with healthcare providers and transplant centers globally. By leveraging an innovative mixture of proprietary testing technology and patient-centric solutions, the company taps into the ongoing demand for improved post-transplant care. Their business model primarily revolves around offering subscription-based services that incorporate longitudinal patient monitoring and data analytics—providing healthcare professionals with a steady flow of actionable insights. CareDx further extends its revenue streams through patient management solutions and digital health offerings, enhancing its footprint in the growing transplant diagnostics market. Beyond diagnostics, CareDx's strategic aspirations see it expanding its portfolio into more integrated healthcare solutions, resonating with healthcare practitioners seeking more personalized and predictive transplant care.

CDNA Intrinsic Value
21.45 USD
Undervaluation 39%
Intrinsic Value
Price
Back to Top